SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ratliff TL. Bacillus Calmette-Guérin (BCG). mechanism of action in superficial bladder cancer. Urol 1991; 37: 811.
  • 2
    Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL. Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem 1999; 274: 45216.
  • 3
    Hudson MA, Brown EJ, Ritchey JK, Ratliff TL. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 1991; 51: 372632.
  • 4
    Coplen DE, Brown EJ, McGarr J, Ratliff TL. Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24. J Urol 1991; 145: 13125.
  • 5
    Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 2000; 86: 838.
  • 6
    Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150: 101823.
  • 7
    Ratliff TL. Role of the immune response in BCG for bladder cancer. Eur Urol 1992; 21: 1721.
  • 8
    Ratliff TL, Gillen DP, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987; 137: 1558.
  • 9
    Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad HD, Jocham D. Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 1993; 150: 19327.
  • 10
    Thanhauser A, Bohle A, Flad HD, Ernst M, Mattern T, Ulmer AJ. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 1993; 37: 10511.
  • 11
    Ratliff TL, Shapiro A, Catalona WJ. Inhibition of murine bladder tumor growth by bacillus Calmette-Guérin: lack of a role of natural killer cells. Clin Immunol Immunopathol 1986; 41: 10815.
  • 12
    Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL. Prognostic value of PPD skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J Urol 1986; 135: 26871.
  • 13
    De Reijke TM, De Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. processing, stability and prognostic value. J Urol 1996; 155: 47782.
  • 14
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy. quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 163642.
  • 15
    Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990; 144: 5964.
  • 16
    O'Donnell MA, Chen X, DeWolf WC. Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules. J Urol 1996; 155: 1030A.
  • 17
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 124851.
  • 18
    Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD, James K. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol 1995; 99: 36975.
  • 19
    Peuchmaur M, Benoit G, Viellefond A, Chevalier A, Lemaigre G, Martin ED, Jardin A. Analysis of mucosal bladder leukocyte subpopulations in patients treated with intravesical bacillus Calmette-Guérin. Urol Res 1989; 17: 299303.
  • 20
    Stover CK, De La Cruz VF, Fuerst TR et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 45660.
  • 21
    O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62: 250814.
  • 22
    Shapiro A, Kelley DR, Oakley DM, Catalona WJ, Ratliff TL. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with bacillus Calmette-Guérin. Cancer Res 1984; 44: 30514.
  • 23
    Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 1569.
  • 24
    Watson MA, Milbrandt J. Expression of the nerve growth factor-regulated NGFI-A and NGFI-B genes in the developing rat. Development 1990; 110: 17383.
  • 25
    Ferguson TA, Dube P, Griffith TS. Regulation of contact hypersensitivity by interleukin 10. J Exp Med 1994; 179: 1597604.
  • 26
    Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, Bohle A. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999; 59: 28347.
  • 27
    Tsuji RF, Kawikova I, Ramabhadran R, Akahira-Azuma M, Taub D, Hugli TE, Gerard C, Askenase PW. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol 2000; 165: 158898.
  • 28
    Kramnik I, Radzioch D, Skamene E. T-helper 1-like subset selection in Mycobacterium bovis bacillus Calmette-Guérin-infected resistant and susceptible mice. Immunol 1994; 81: 61825.
  • 29
    Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 12059.
  • 30
    Martinez-Pineiro JA, Jimenez-Leon J, Martinez-Pineiro LJr, Fiter L, Mosteiro JA, Navarro J, Garcia-Matres MJ, Carcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143: 5026.
  • 31
    Malmstrom P. Improved patient outcomes with BCG immunotherapy vs. chemotherapy – Swedish and worldwide experience. Eur Urol 2000; 37: 1620.
  • 32
    Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner SM, Ratliff TL, Catalona WJ. Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J Urol 1988; 139: 93540.
  • 33
    De Jager R, Guinan P, Lamm D et al. Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette-Guérin. Overview analysis of six phase II clinical trials. Urology 1991; 38: 50713.
  • 34
    Herr HW, Pinsky CM, Whitmore WF. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 2657.
  • 35
    Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 57380.
  • 36
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 11249.
  • 37
    Herr HW, Whitmore WF. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors. incidence, possible pathogenesis and management. J Urol 1987; 138: 2924.
  • 38
    Snodgrass MJ, Hanna MGJ. Ultrastructural studies of histiocyte–tumor cell interactions during tumor regression after intralesional injection of Mycobacterium bovis. Cancer Res 1973; 33: 70116.
  • 39
    Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, Studer UE. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. Randomized Controlled Trial. J Urol 1996; 155: 4837.
  • 40
    Ibsen MW, Bakken V, Jonsson R, Hordnes K. Immune responses in mice after gastric and subcutaneous immunization with BCG. Scand J Immunol 1997; 46: 27480.
  • 41
    Zlotta AR, Drowart A, Huygen K et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 1997; 109: 15765.
  • 42
    Haaff EO, Catalona WJ, Ratliff TL. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986; 136: 9704.
  • 43
    Ladel CH, Daugelat S, Kaufmann SH. Immune response to Mycobacterium bovis Calmette-Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 1995; 25: 37784.
  • 44
    Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minoprio P. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and – dependent phases of Mycobacterium avium infection. Infect Immun 1994; 62: 396271.
  • 45
    Stenger S, Mazzaccaro RJ, Uyemura K et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997; 276: 16847.
  • 46
    Zbar B, Bernstein I, Bartlett GL, Hanna MG, Rapp HJ. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst 1972; 49: 11930.
  • 47
    Kullberg MC, Rothfuchs AG, Jankovic D, Caspar P, Wynn TA, Gorelick PL, Cheever AW, Sher A. Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice. cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun 2001; 69: 423241.
  • 48
    Ito A, Bebo BFJ, Matejuk A, Zamora A, Silverman M, Fyfe-Johnson A, Offner H. Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol 2001; 167: 54252.
  • 49
    Fujimoto T, O'Donnell MA, Szilvasi A, Yang H, Duda RB. Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 1996; 42: 2804.
  • 50
    Bahnson RR, Ratliff TL. In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J Urol 1990; 144: 1725.
  • 51
    Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 1992; 52: 428690.
  • 52
    Patard JJ, Chopin DK, Boccon-Gibod L. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. World J Urol 1993; 11: 1658.
  • 53
    Jakobson E, Jonsson G, Bjorck P, Paulie S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int J Cancer 1998; 77: 84953.
  • 54
    O'Donnell MA, Szilvasi A, Luo Y, DeWolf WC. Fas mediated killing of transitional cell carcinoma. J Urol 1996; 155: 567A.
  • 55
    Miller MI, Klein LT, Ikeguchi E, Buttyan R, Katz A, Raffo J, Olsson C, Connor JP. Anti fas antibody mediated apoptosis in bladder tumor cells: a potential intravesical therapeutic agent. J Urol 1996; 155: 569A.